FDA Officially Ends Semaglutide Shortage After Nearly 3 Years — What This Means for Ozempic and Wegovy Patients (2026)

It's official: the semaglutide shortage is over. The U.S. Food and Drug Administration has confirmed that Novo Nordisk is now meeting or exceeding both current and projected U.S. demand for Wegovy (semaglutide for obesity) and Ozempic (semaglutide for type 2 diabetes), ending a shortage that began in early 2022 and reshaped the entire weight-loss medication landscape.

The announcement marks the formal close of one of the most disruptive drug shortages in recent memory — one that drove a 442% increase in prescription fills between 2021 and 2023, spawned a multi-billion-dollar compounded GLP-1 industry, and made semaglutide a household name in American healthcare.

What the FDA's Decision Actually Means

When the FDA removes a drug from its shortage list, it sends a clear signal to regulators, pharmacies, and enforcement authorities: supply is no longer the problem. For patients, this has immediate practical consequences:

• Easier prescription fills: Pharmacies that had previously been rationing semaglutide supplies or turning away new prescriptions should now be able to fill orders more reliably. Patients who have experienced "out of stock" notifications from their pharmacy should see that improve.
• Less dose restriction: During peak shortage periods, some prescribers limited patients to lower doses due to supply constraints. With supply normalized, clinicians can prescribe the therapeutically appropriate dose without worrying about availability.
• Competitive pricing pressure: As supply normalizes, market forces typically push cash-pay prices down over time. This is already playing out — programs like TrumpRx offer Ozempic and Wegovy at roughly $350/month, a dramatic reduction from pre-shortage list prices.

However, the FDA was careful to note that localized availability issues may still occur. Supply chain logistics mean that certain regions or pharmacy chains may lag behind the national picture. Patients should contact their specific pharmacy to confirm availability.

A Lawsuit in the Wings

Not everyone is celebrating. The Outsourcing Facilities Association (OFA) — a trade group representing companies that produce compounded pharmaceuticals — has sued the FDA, calling the agency's decision to end the semaglutide shortage "reckless and arbitrary."

The legal challenge mirrors a nearly identical lawsuit the OFA filed when the FDA ended the tirzepatide shortage earlier this year. In that case, the FDA's determination that compounded tirzepatide could no longer be produced triggered a 90-day wind-down period for pharmacies. The courts ultimately upheld the FDA's authority to make that determination.

The OFA argues that demand still outpaces supply in certain regions and patient populations, and that abruptly cutting off compounded semaglutide access will harm patients who depend on it for affordability. The FDA counters that its shortage determinations are based on comprehensive data from manufacturers, distributors, and pharmacy dispensing records — and that Novo Nordisk's production capacity now meets the market's needs.

Legal experts expect this challenge, like the tirzepatide suit before it, to face significant headwinds. Courts have historically deferred to the FDA's technical expertise in shortage determinations. But until any injunction is issued, FDA enforcement against compounded semaglutide will proceed on the announced schedule.

The Clock Is Now Running for Compounded Semaglutide

Here's what matters most for the estimated 2-4 million patients currently using compounded semaglutide: with the shortage officially ended, the FDA's regulatory authority to permit compounded versions of the drug disappears.

Under the Federal Food, Drug, and Cosmetic Act, compounding of FDA-approved drugs is generally not permitted unless a specific shortage or patient-specific medical need applies. The end of the shortage removes the main legal umbrella that has protected large-scale compounded semaglutide operations.

While the FDA has not yet issued a formal 90-day deadline specifically for semaglutide (as it did for tirzepatide), enforcement actions are expected to follow. Patients using compounded versions should:

1. Speak with their prescribing provider immediately about transitioning to brand-name Wegovy or Ozempic
2. Explore all pricing pathways — TrumpRx ($350/month for uninsured), manufacturer savings cards (up to $25/month for commercially insured eligible patients), and GoodRx telemedicine options
3. Do not assume your supply will continue — compounding pharmacies that have been supplying semaglutide face significant legal exposure and will be winding down operations

The Bigger Picture: The Compounded GLP-1 Era Is Ending

The FDA's semaglutide shortage determination, combined with the already-announced 90-day deadline for tirzepatide and new enforcement actions targeting misleading marketing of compounded GLP-1 products, signals a comprehensive regulatory sweep of the compounded GLP-1 market.

What began as a workaround for genuine supply shortages has, in the FDA's view, become an unregulated shadow market for drugs that don't meet the safety and efficacy standards of their FDA-approved counterparts. The compounded products don't carry FDA labeling, haven't been tested for the specific formulations in use, and have varied wildly in quality — with some reports of contaminated or degraded products reaching patients.

At the same time, the convergence of brand-name price reductions, the TrumpRx program, GoodRx's telemedicine service, and now the Medicare Zepbound deal suggests that the affordability argument for compounded GLP-1s is weakening. For many patients, the price gap between compounded and brand-name options has narrowed significantly.

"The shortage was real, and it drove real innovation in how patients accessed these medications," said Dr. Harpreet Anand, a clinical pharmacologist. "But that chapter is closing. The regulatory environment is normalizing, and the brands are responding with more aggressive pricing to fill the gap."

What Patients Should Do Now

Whether you're currently on brand-name Ozempic or Wegovy and dealing with fill issues, or you're on a compounded version and wondering what's next, here's your action plan:

• Brand-name patients: Filling should become easier over the coming weeks and months. If you're still hitting supply issues, call ahead to your pharmacy and ask them to flag you for priority fulfillment when stock arrives.
• Compounded semaglutide patients: Contact your provider now. Transition planning takes time — you'll need a new prescription, possibly a prior authorization, and you'll want to lock in savings programs before supplies get tight again at the brand level.
• Cost-concerned patients: The TrumpRx program, GoodRx For Weight Loss (oral semaglutide starting at $149/month), and manufacturer programs all offer paths to brand-name GLP-1 access at significantly reduced cost.

Will brand-name Ozempic and Wegovy be easier to find now?

Yes — the FDA's shortage declaration ending signals that Novo Nordisk's production is meeting national demand. Availability should improve at most pharmacies, though some regional variation may persist in the short term.

What happens to compounded semaglutide now?

With the shortage officially ended, the FDA's legal basis for permitting large-scale compounded semaglutide production is removed. Formal enforcement deadlines are expected to follow, similar to the 90-day deadline issued for tirzepatide. Patients on compounded versions should begin transitioning to brand-name medications now.

Does this affect the price of Ozempic and Wegovy?

Not immediately at the list price level, but market access programs have already dramatically reduced effective costs. Programs like TrumpRx offer brand-name Wegovy at roughly $350/month. These options are available now regardless of insurance status for eligible patients.